Accumulation of murine amyloid-β mimics early Alzheimer's disease

被引:40
|
作者
Krohn, Markus [1 ,2 ,3 ]
Bracke, Alexander [4 ]
Avchalumov, Yosef [5 ]
Schumacher, Toni [3 ]
Hofrichter, Jacqueline [3 ]
Paarmann, Kristin [1 ,2 ,3 ]
Froehlich, Christina [3 ]
Lange, Cathleen [3 ]
Bruening, Thomas [1 ,2 ,3 ]
Halbach, Oliver von Bohlen Und
Pahnke, Jens [1 ,2 ,3 ,6 ,7 ]
机构
[1] Univ Oslo UiO, Dept Neuropathol, Translat Neurodegenerat Res & Neuropathol Lab, Oslo, Norway
[2] Oslo Univ Hosp OUS, Oslo, Norway
[3] Univ Rostock, Dept Neurol, D-18055 Rostock, Germany
[4] Ernst Moritz Arndt Univ Greifswald, Dept Anat, Greifswald, Germany
[5] Univ Rostock, Dept Physiol, D-18055 Rostock, Germany
[6] Univ Lubeck, LIED, Lubeck, Germany
[7] Leibniz Inst Plant Biochem, Dept Bioorgan Chem, Halle, Germany
关键词
ABCC1; neprilysin; ABCB1; Alzheimer's disease; MCI; amyloidosis; BLOOD-BRAIN-BARRIER; CENTRAL-NERVOUS-SYSTEM; MOUSE MODEL; P-GLYCOPROTEIN; PRECURSOR PROTEIN; IN-VIVO; A-BETA; NEUTRAL ENDOPEPTIDASE; SYNAPTIC PLASTICITY; PYRAMIDAL NEURONS;
D O I
10.1093/brain/awv137
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Almost all mouse models of Alzheimer's disease use expression of human transgenes to trigger amyloid pathology. Krohn <italic toggle="yes">et al. introduce a new mouse model without transgene expression that, in common with patients with sporadic Alzheimer's disease, shows reduced amyloid-beta clearance. The model shows pathology reminiscent of early-stage Alzheimer's disease.Almost all mouse models of Alzheimer's disease use expression of human transgenes to trigger amyloid pathology. Krohn <italic toggle="yes">et al. introduce a new mouse model without transgene expression that, in common with patients with sporadic Alzheimer's disease, shows reduced amyloid-beta clearance. The model shows pathology reminiscent of early-stage Alzheimer's disease.Amyloidosis mouse models of Alzheimer's disease are generally established by transgenic approaches leading to an overexpression of mutated human genes that are known to be involved in the generation of amyloid-beta in Alzheimer's families. Although these models made substantial contributions to the current knowledge about the 'amyloid hypothesis' of Alzheimer's disease, the overproduction of amyloid-beta peptides mimics only inherited (familiar) Alzheimer's disease, which accounts for < 1% of all patients with Alzheimer's disease. The inherited form is even regarded a 'rare' disease according to the regulations for funding of the European Union ( ext-link-type="uri" xlink:href="http://www.erare.eu">www.erare.eu). Here, we show that mice that are double-deficient for neprilysin (encoded by <italic toggle="yes">Mme), one major amyloid-beta-degrading enzyme, and the ABC transporter ABCC1, a major contributor to amyloid-beta clearance from the brain, develop various aspects of sporadic Alzheimer's disease mimicking the clinical stage of mild cognitive impairment. Using behavioural tests, electrophysiology and morphological analyses, we compared different ABC transporter-deficient animals and found that alterations are most prominent in neprilysin x ABCC1 double-deficient mice. We show that these mice have a reduced probability to survive, show increased anxiety in new environments, and have a reduced working memory performance. Furthermore, we detected morphological changes in the hippocampus and amygdala, e.g. astrogliosis and reduced numbers of synapses, leading to defective long-term potentiation in functional measurements. Compared to human, murine amyloid-beta is poorly aggregating, due to changes in three amino acids at N-terminal positions 5, 10, and 13. Interestingly, our findings account for the action of early occurring amyloid-beta species/aggregates, i.e. monomers and small amyloid-beta oligomers. Thus, neprilysin x ABCC1 double-deficient mice present a new model for early effects of amyloid-beta-related mild cognitive impairment that allows investigations without artificial overexpression of inherited Alzheimer's disease genes.
引用
收藏
页码:2370 / 2382
页数:13
相关论文
共 50 条
  • [31] Amyloid-β and Tau at the Crossroads of Alzheimer's Disease
    Gallardo, Gilbert
    Holtzman, David M.
    TAU BIOLOGY, 2019, 1184 : 187 - 203
  • [32] Amyloid-β-targeting immunotherapies for Alzheimer's disease
    Jin, Yi
    Du, Qiaofei
    Song, Mingjie
    Kang, Ruixin
    Zhou, Jianping
    Zhang, Huaqing
    Ding, Yang
    JOURNAL OF CONTROLLED RELEASE, 2024, 375 : 346 - 365
  • [33] Soluble Amyloid-β Consumption in Alzheimer's Disease
    Espay, Alberto J.
    Sturchio, Andrea
    Schneider, Lon S.
    Ezzat, Kariem
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 82 (04) : 1403 - 1415
  • [34] Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
    Song, Zijian
    Zheng, Miao
    Ding, Jiahui
    Xu, Yidi
    Ji, Miao-Jin
    Liu, Chao
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2021, (170):
  • [35] URMC-099 facilitates amyloid-β clearance in a murine model of Alzheimer’s disease
    Tomomi Kiyota
    Jatin Machhi
    Yaman Lu
    Bhagyalaxmi Dyavarshetty
    Maryam Nemati
    Gang Zhang
    R. Lee Mosley
    Harris A. Gelbard
    Howard E. Gendelman
    Journal of Neuroinflammation, 15
  • [36] URMC-099 facilitates amyloid-β clearance in a murine model of Alzheimer's disease
    Kiyota, Tomomi
    Machhi, Jatin
    Lu, Yaman
    Dyavarshetty, Bhagyalaxmi
    Nemati, Maryam
    Zhang, Gang
    Mosley, R. Lee
    Gelbard, Harris A.
    Gendelman, Howard E.
    JOURNAL OF NEUROINFLAMMATION, 2018, 15
  • [37] Neuronal amyloid-β accumulation within cholinergic basal forebrain in ageing and Alzheimer's disease
    Baker-Nigh, Alaina
    Vahedi, Shahrooz
    Davis, Elena Goetz
    Weintraub, Sandra
    Bigio, Eileen H.
    Klein, William L.
    Geula, Changiz
    BRAIN, 2015, 138 : 1722 - 1737
  • [38] Early and Late Pathomechanisms in Alzheimer’s Disease: From Zinc to Amyloid-β Neurotoxicity
    Andrzej Szutowicz
    Hanna Bielarczyk
    Marlena Zyśk
    Aleksandra Dyś
    Anna Ronowska
    Sylwia Gul-Hinc
    Joanna Klimaszewska-Łata
    Neurochemical Research, 2017, 42 : 891 - 904
  • [39] Plasma Insulin Predicts Early Amyloid-β Pathology Changes in Alzheimer's Disease
    Chen, Yu-Han
    Wang, Zhi-Bo
    Liu, Xi-Peng
    Mao, Zhi-Qi
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 100 (01) : 321 - 332
  • [40] Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
    Pereira, Joana B.
    Janelidze, Shorena
    Smith, Ruben
    Mattsson-Carlgren, Niklas
    Palmqvist, Sebastian
    Teunissen, Charlotte E.
    Zetterberg, Henrik
    Stomrud, Erik
    Ashton, Nicholas J.
    Blennow, Kaj
    Hansson, Oskar
    BRAIN, 2021, 144 : 3505 - 3516